Clinical Trial Update: Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations [Phase 1]

View source ↗

Summary

TYRA-200 is being studied in a Phase 1 trial to assess safety and anti-tumor activity in advanced cholangiocarcinoma with FGFR2 alterations. The trial is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• TYRA-200

Snippet

Sponsor: Tyra Biosciences, Inc | Conditions: Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma | Phase 1 | Status: RECRUITING